Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Descriptor: Met expression


Reference Number: 669
Jeffers M, Koochekpour S, Fiscella M, Sathyanarayana BK, Vande Woude GF. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor. Oncogene. 17, 2691-700 (1998)
PubMed link      E-mail link

Reference Number: 1006
Taylor GA, Jeffers M, Webb CP, Koo HM, Anver M, Sekiguchi K, Vande Woude GF. Decreased fibronectin expression in Met/HGF-mediated tumorigenesis. Oncogene. 17, 1179-83 (1998)
PubMed link      E-mail link

Reference Number: 1009
Lee JH, Gao CF, Lee CC, Kim MD, Vande Woude GF. An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med. 38, 565-73 (2006)
PubMed link      E-mail link

Reference Number: 1011
Hay R, Cao B, Tsarfaty I, Tsarfaty G, Resau J, Woude GV. Grappling with metastatic risk: bringing molecular imaging of Met expression toward clinical use. J Cell Biochem Suppl. 39, 184-93 (2002)
PubMed link      E-mail link

Reference Number: 1015
Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, Lipson KE, Woude GF, Webb CP. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A. 98, 10722-7 (2001)
PubMed link      E-mail link

Reference Number: 1017
Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 19, 5582-9 (2000)
PubMed link      E-mail link

Reference Number: 1019
Webb CP, Taylor GA, Jeffers M, Fiscella M, Oskarsson M, Resau JH, Vande Woude GF. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene. 17, 2019-25 (1998)
PubMed link      E-mail link

Reference Number: 1211
Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 7, 504-16 (2008)
PubMed link      E-mail link

Reference Number: 1212
Corso S, Migliore C, Ghiso E, De Rosa G, Comoglio PM, Giordano S. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene. 27, 684-93 (2008)
PubMed link      E-mail link

Reference Number: 1213
Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 27, 85-94 (2008)
PubMed link      E-mail link

Reference Number: 1239
Rajadurai CV, Havrylov S, Zaoui K, Vaillancourt R, Stuible M, Naujokas M, Zuo D, Tremblay ML, Park M. Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia. J Cell Sci. 125, 2940-53 (2012)
PubMed link      E-mail link

Reference Number: 1249
Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell. 6, 61-73 (2004)
PubMed link      E-mail link

Reference Number: 1250
Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 3, 347-61(2003)
PubMed link      E-mail link

Reference Number: 1252
Peschard P, Ishiyama N, Lin T, Lipkowitz S, Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J Biol Chem. 279, 29565-71 (2004)
PubMed link      E-mail link

Reference Number: 1253
Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A. 91, 4731-5 (1994)
PubMed link      E-mail link

Reference Number: 1292
Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT, Noll JE, Coffill CR, Lane DP, Sansom OJ, Neilsen PM, Norman JC, Vousden KH. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene. 32, 1252-65 (2013)
PubMed link      E-mail link

Reference Number: 1583
Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. Int J Cancer. 135, 2305-16 (2014)
PubMed link      E-mail link

Reference Number: 1624
Webster DE, Barajas B, Bussat RT, Yan KJ, Neela PH, Flockhart RJ, Kovalski J, Zehnder A, Khavari PA. Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition. Genome Res. 24, 751-60 (2014)
PubMed link      E-mail link